BIO BIO 2016 Convention

AMR focus

Global workshop for novel anti-infectives


CO-ADD AT BIO 2016 Convention, San Francisco, United States

This event has now finished. Congratulations to Bioversys (Marc Gitzinger- judges award) and Epibiome (Nick Conley - people's choice award), winners of the company pitches rapid fire session.You can still sign up for updates. Company presentations are available for download here.

AMR Focus: global workshop for novel anti-infectives
June 6, 2016. 11.00am-12.30pm, Moscone Convention Center,South Room 105


Join us at the BIO Convention 2016 for a workshop dedicated to showcasing novel antibiotics and AMR innovation. Hosted by the Innovative Medicines’ Initiative (IMI), The Wellcome Trust-funded Community For Open Antimicrobial Drug Discovery and the IMI funded ENABLE project, the workshop highlights the global tools available to support the development of novel anti-infectives and presents 10 innovative small company programmes from six countries.

The workshop is open to all BIO attendees and is free of charge.  Its mission is to bring together all actors involved in AMR, including industry large and small, universities, investors, expert scientific and business support, funders, policy makers and regulatory bodies.
Company presentations will be assessed by an expert panel and the audience, selecting the best presentation for international promotion following the workshop.

1100: Dr Pierre Meulien, Executive Director Innovative Medicines Initiative
1110: Professor Matthew Cooper, University of Queensland - Community for Open Antimicrobial Drug Discovery
1120: Dr Claire Skentelbery, European Biotechnology Network – ENABLE project
11.30: Company presentations - rapid fire session
•    Antabio – France
•    Bioversys – Switzerland
•    Diatheva – Italy
•    Epibiome – United States
•    Morphochem – Germany
•    Neem Biotech – UK
•    Novabiotics – UK
•    Polyphor – Switzerland
•    RedX – UK
•    VICAL – United States

MC: Mathilde Desselle, University of Queensland - Community for Open Antimicrobial Drug Discover


•    ENABLE project: a 6 year, €85 million project funded by the Innovative Medicines Initiative (IMI) that develops gram negative programmes through to Phase II clinical trials
•    CO-ADD project: a Wellcome Trust/University of Queensland funded open-access project that provides free antimicrobial screening for compound libraries from academics world-wide
•    Innovative Medicines Initiative: A public private partnership between the European Commission and European Federation of Pharmaceutical Industry Associations (EFPIA) which is funding ENABLE as part of the New Drugs for Bad Bugs series of projects.

The hosts are also presenting:

BIO 2016 "Bridging the Gap: Alignment of Global Antibiotic R&D Partnerships" panel discussion
June 8, 2016, 3:30 PM–4:30 PM, Room West 3004, Session ID 6880.


To schedule a meeting with a CO-ADD representative at the BIO 2016 convention, please contact us.